Innovating Works

RESEARCH FOUNDATION OSPEDALE MAGGIORE DI...

Desconocido
EURO SHOCK: Testing the value of a novel strategic approach and its cost efficacy to improve the poor outcomes i... FONDAZIONE PER LA RICERCA OSPEDALE MAGGIORE DE BERGAMO participó en un H2020: H2020-SC1-2016-2017 Heart attacks are common and can leave survivors suffering cardiogenic shock (CGS), with its extremely high risk of early death (42% versus...
2017-12-05 - 2022-12-31 | Financiado
CureCN: Adeno Associated Virus Vector Mediated Liver Gene Therapy for Crigler Najjar Syndrome FONDAZIONE PER LA RICERCA OSPEDALE MAGGIORE DE BERGAMO participó en un H2020: H2020-SC1-2016-2017 Crigler-Najjar syndrome (CN) is a rare recessive disorder caused by mutations in the uridine diphosphate glucuronosyltransferase 1A1(UGT1A1)...
2017-12-05 - 2023-12-31 | Financiado
BETA3_LVH: A multi center randomized placebo controlled trial of mirabegron a new beta3 adrenergic receptor a... FONDAZIONE PER LA RICERCA OSPEDALE MAGGIORE DE BERGAMO participó en un H2020: H2020-PHC-2014-2015 Patients with cardiovascular risk factors, e.g. hypertension and obesity are at risk of developing heart failure with preserved ejection fra...
2015-04-15 - 2022-08-31 | Financiado
NEPHSTROM: Novel Stromal Cell Therapy for Diabetic Kidney Disease FONDAZIONE PER LA RICERCA OSPEDALE MAGGIORE DE BERGAMO participó en un H2020: H2020-PHC-2014-2015 Type 2 diabetes will affect >500 million adults by 2040 and its secondary complications will generate enormous socioeconomic costs - in part...
2015-04-08 - 2021-10-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.